

Medicaid Clinical Advisory Committee Activity Summary SFY21

October 2021

Table Contents

Medicaid Clinical Advisory Committee Background and Objectives	2
Committee Members	4
Review of Medical Policy Criteria	6

Medicaid Clinical Advisory Committee Background and Objectives

The establishment and requirements of the Iowa Medicaid Enterprise (IME) Clinical Advisory Committee (CAC) are contained in House File 841 and the Medicaid CAC was initiated in 2006. The purpose of the Medicaid CAC is to increase the efficiency, quality, and effectiveness of the Iowa Medicaid healthcare system. The Medicaid CAC provides a process for physicians and other healthcare providers to promote quality care, member safety, and fiscal responsibility through a discussion of Medicaid benefits and healthcare services criteria.

The Medicaid CAC is charged with recommending clinically appropriate healthcare utilization management and coverage decisions for the Iowa Medicaid program. This annual report summarizes the recommendations made by the Medicaid CAC and those adopted by rule.

The Medicaid CAC performs:

- Technology and therapeutics review for advanced therapy and new technology.
- Administrative support through its review and recommendations regarding policy issues.
- Criteria review with recommendations for changes.

The Medicaid CAC meetings are subject to the open committee rules in Chapter 21 of the Iowa Administrative Code. All meetings are publicly announced on the DHS website a minimum of 10 days prior to the scheduled date and time. All meeting agendas, minutes, a summary of Medicaid CAC responsibilities, and Medicaid CAC questions and answers are posted on the DHS website.

Appointments are for 3 years and each member may be reappointed for one additional 3-year term.

The IME Quality Improvement Organization (QIO) Services unit is responsible for the administration of the Medicaid CAC. The IME medical director, Dr. William (Bill) Jagiello, chairs the Medicaid CAC. The chair of the Medicaid CAC may only vote in the situation that the committee has a tie vote.

Else Umbreit, PharmD, joined QIO Services in April 2021. She has 5 years of experience working in the managed care setting and will be applying her knowledge in the review and development of criteria for physician administered medications, as well as assist with new code reviews.

The Medicaid managed care organizations send clinical representation, typically an MCO medical director, to the Medicaid CAC meetings. The MCO medical directors are not voting members of the Medicaid CAC; however, they contribute to clinical criteria discussions to ensure criteria are implemented consistently.

The Medicaid CAC evaluates the clinical aspects of IME coverage policies and medical management strategies to maximize both quality healthcare and cost effectiveness. The Medicaid CAC provides recommendations in the early stages of policy development and change, through collaboration with the Policy unit, which enhances buy-in from the Medicaid provider network.

Committee Members

Clarice Blanchard PA-C, MMS

Clarice Blanchard graduated from Luther College in Decorah, Iowa, with a Bachelor of Arts in Biology and Psychology in 1996. She then received her physician assistant training at St. Louis University in St. Louis, Missouri, graduating in 1999. Clarice has practiced in family medicine and emergency medicine at Madison County Healthcare System in Winterset, Iowa, since 2001.

Sherry Buske, NP-C, MSN, MSHA, BSN, CDE

Ms. Buske completed her RN training at St. Luke's School of Nursing in Cedar Rapids, lowa, in 1975. She obtained her BSN from Mercy College of Health Sciences in Des Moines, lowa, in 1999. She obtained her Masters in Health Service Administration from the University of St. Francis in Joliet, Illinois, in 2003 and her Masters in Nursing as a family nurse practitioner from Allen College in Waterloo, Iowa, in 2009. Ms. Buske is certified in diabetes education and management. She retired from practice in June 2020. Ms. Buske retired from the Medicaid CAC following the April 2021 meeting.

Dana Danley, MD

Dr. Danley graduated from the University of Iowa College of Medicine, Iowa City, Iowa, in 1998. She completed her post-graduate training in family practice at Broadlawns Medical Center in 2001and is board-certified in Family Practice. Dr. Danley is an active educator in medical student education as an Adjunct Assistant Family Medicine faculty at Des Moines University and an Adjunct Clinical Associate Professor at the Carver College of Medicine. Dr. Danley also is a faculty member of the Broadlawns Medical Center Family Medicine Residency and has received several awards for teaching. She currently practices at Broadlawns Medical Clinic in Des Moines, Iowa.

Polly Ferguson, MD

Dr. Ferguson graduated from the University of Iowa Carver College of Medicine in Iowa City, Iowa, in 1990. She completed a pediatric residency in 1993, a pediatric rheumatology and immunology fellowship in 1996 and a post-doctoral research fellowship in 2000 at the University of Virginia in Charlottesville, Virginia. Dr. Ferguson joined the faculty at the University of Alabama at Birmingham in 2000 and subsequently took a faculty position at the University of Iowa in 2002 where she remains. She currently is a Professor of Pediatrics and Director of Pediatric Rheumatology, Allergy, and Immunology at the University of Iowa Stead Family Department of Pediatrics.

Alexandra K. Hubbell, DO

Dr. Hubbell graduated from Des Moines University in 2007 and completed her residency at Iowa Lutheran Family Medicine Program in Des Moines, Iowa, in 2013. Dr. Hubbell is the Associate Program Director at the Iowa Lutheran Family Medicine Residency.

Kathleen Lange, MD

Dr. Lange graduated from the University of Iowa College of Medicine in Iowa City, Iowa, in 1992. She completed her residency at Iowa Lutheran Hospital in Des Moines, Iowa, in 1997. She actively participates in several professional affiliations and memberships. Dr. Lange currently practices at Chariton Valley Medical Center in Centerville, Iowa, in family practice.

Stephen R. Mandler DO

Dr. Mandler is board certified in Adult, Child, and Adolescent Psychiatry. He did his Medical Internship at Oregon Health and Sciences University, and Residency and Fellowship at The Menninger Clinic. He is currently the Chief Medical Officer at Orchard Place. Orchard Place annually serves more than 10,000 children across Iowa from birth to age 22 through a wide variety of mental health services for children and young adults. Previously he served as Regional Medical Officer Psychiatrist, US Department of State, Foreign Service, and worked in Afghanistan, Mexico, and West Africa. He has served on the faculty of Oregon Health Sciences University and Portland State University's Graduate Program of Infant/Toddler Mental Health. Dr. Mandler is an appointed member of the Iowa Council for Early ACCESS.

Andrea Silvers, MD

Dr. Silvers graduated from the University of Iowa College of Medicine in Iowa City, Iowa in 1999. She completed her residency in family practice at Iowa Lutheran Hospital in Des Moines, Iowa, in 2002. Dr. Silvers currently practices at Norwalk Family Physicians in Norwalk, Iowa in family practice. Dr. Silvers retired from the Medicaid CAC following the April 2021 CAC meeting.

Dennis Zachary, MD

Dr. Zachary graduated from the Mayo Medical School in Rochester, Minnesota in 1984. He completed his post-graduate training in family practice at North Memorial Branch at the University of Minnesota in 1987. He is board-certified in family practice, geriatric medicine, and sports medicine. He actively participates in several professional affiliations and memberships. He has been the recipient of numerous military honors. Dr. Zachary currently practices at Mercy South Medical Clinic in Des Moines, Iowa, in family practice.

Review of IME Medical Policy Criteria

A key function of the Medicaid CAC is to provide IME with an annual review of the criteria utilized for physician-administered drugs and medical review. Using the wide range of expertise represented by the Medicaid CAC members, review of each established and new criteria considers standards of practice, the effect of treatment on quality of life, functional status, and other relevant aspects of the health of Medicaid members.

QIO Services also recruits specialists throughout lowa to review the following specialized criteria annually:

- Bone marrow and/or peripheral blood stem cell transplant,
- Heart transplant,
- Liver transplant,
- Lung transplant,
- Pancreas transplant,
- Orthodontic procedures, and
- Periodontic procedures.

The table on the following pages list the criteria reviewed by the Medicaid CAC during SFY21.

Criteria	Actioned
Adakveo (crizanlizumab-tmca)	Jan 2021
Augmentative Communication Systems	Apr 2021
Back-up Ventilator	Jul 2020
Bariatric Surgery (CoE/MBSAQIP)	Jan 2021
Bavenico (avelumab)	Oct 2020
Blepharoplasty	Apr 2021
Bone Marrow/Peripheral Blood Stem Cell Transplant	Oct 2020
Botulinum Toxins	Jan 2021
Brineura (cerliponase alpha)	Oct 2020
Ceiling Track Lifts and/or Electric Patient Lifts	Oct 2020
Children's Mental Health Waiver Level of Care	Jul 2020
Chromosomal Microarray Analysis	Jan 2021
Cochlear Implant	Oct 2020
Cochlear Implant Repair/Replacement	Oct 2020
Consumer-Directed Attendant Care	Apr 2021
Continuous Glucose Monitor	Oct 2020
Crysvita (burosumab)	Jul 2020
Crysvita (burosumab-twza)	Oct 2020
CT Colonography	Oct 2020

Criteria	Actioned
Elaprase (idursulfase)	Jul 2020
Enhertu (fam-trastuzumab deruxtecan-nxki)	Apr 2021
Enteral Products and Supplies	Jul 2020
Environmental Modification-Adaptive Devices	Jan 2021
Exondys 51 (eteplirsen)	Apr 2021
Fecal Microbiota Transplantation	Jan 2021
Gait Trainer/Stander	Apr 2021
Gene Expression Profiling for the management of Breast Cancer	Jul 2020
Genetic Testing (excludes BRCA testing and 21-gene RT-PCR assays)	Apr 2021
Genetic testing for Hereditary Breast and Ovarian Cancer Syndrome	Jan 2021
Habilitation Eligibility	Jul 2020
Heart Transplant	Oct 2020
Hemangioma Removal	Oct 2020
High Frequency Chest Wall Oscillators	Jan 2021
Home and Vehicle Modification	Oct 2020
Iluvien & Retisert (cluocinolone acetate intravitreal implants)	Jul 2020
Imaging for Incidental Lesions	Jul 2020
Imfinzi (durvalumab)	Oct 2020
Jelmyto (mitomycin gel)	Apr 2021
Kadcyla (ado-trastuzumab emutansine)	Jul 2020
Keytruda (pembrolizumab)	Jan 2021
Krystexxa (pegloticase)	Apr 2021
Kymriah (tisagenlecleucel)	Jan 2021
Laser Linear Accelerator Based Stereotactic Radiosurgery (LABSR)	Oct 2020
Liver Transplant	Oct 2020
Lutathera (lutetium Lu 177 dotatate)	Jan 2021
Luxturna (voretigene neparvovec-rzyl)	Apr 2021
Mobility related Device Purchase	Oct 2020
Namenda (memantine) for Autism Spectrum Disorder	Oct 2020
Negative Pressure Wound Therapy	Apr 2021
Nipple Tattooing	Oct 2020
Non-Invasive Prenatal Testing for Aneuploidy Using Cell Free DNA	Jan 2021
Nursing Facility Level of Care	Apr 2021
Ocrevus (ocrelizumab)	Oct 2020
Orbactiv (oritavancin)	Oct 2020
Orthodontic Procedures	Oct 2020
Pancreas Transplant	Oct 2020
Panniculectomy	Oct 2020
Pediatric Skilled Level of Care	Oct 2020

Criteria	Actioned
Percussors	Jul 2020
Periodontic Procedures	Oct 2020
Personal Care Services for Children	Apr 2021
Pneumatic Compression Devices	Jul 2020
Power Seat Elevation for Power Wheelchairs	Oct 2020
Power Wheelchair Attendant Controls	Oct 2020
Private Duty Nursing for Children	Apr 2021
Radicava (edaravone)	Oct 2020
Reduction Mammoplasty/Mastopexy	Jul 2020
Risk Reduction Mastectomy	Jul 2020
Safety Beds	Apr 2021
Septoplasty/Rhinoplasty	Apr 2021
Shower/Commode Chair	Apr 2021
Skilled Level of Care	Apr 2021
Spinraza (nusinersen)	Oct 2020
Spravato (esketamine)	Apr 2021
Strollers and Wheelchairs for Safety	Jul 2020
Tecartus (brexucabtagene autoleucel)	Jan 2021
Tepezza (teprotumumab-trbw)	Apr 2021
Transcranial Magnetic Stimulation	Oct 2020
Trodelvy ()	Jan 2021
Tysabri (natalizumab)	Oct 2020
Vagus Nerve Stimulator	Apr 2021
Visual Aids and Vision Therapy	Oct 2020
Vitamin, Mineral, Amino Acid Supplements	Apr 2021
Vivitrol (naltrexone)	Oct 2020
Vyepti (sacituzumab govitecan-hziy)	Jan 2021
Vyondys 53 (golodirsen)	Apr 2021
Wearable Automatic External Defibrillator	Jul 2020
Whole Exome Sequencing	Jan 2021
Yescarta (axicabtagene ciloleucel)	Jan 2021
Zolgensma (onasemnogene abeparvovec-xioi)	Oct 2020